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ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a complex, multidimensional and heterogeneous
disease. The main purpose of the present study was to identify clinical phenotypes through cluster
analysis in adults suffering from COPD. A retrospective study was conducted on 178 COPD
patients in stable state recruited from ambulatory care at University hospital of Liege. All patients
were above 40 years, had a smoking history of more than 20 pack years, post bronchodilator
FEV1/FVC <70% and denied any history of asthma before 40 years. In this study, the patients were
described by a total of 84 mixed sets of variables with some missing values. Hierarchical clustering
on principal components (HCPC) was applied on multiple imputation. In the final step, patients
were classified into homogeneous distinct groups by consensus clustering. Three different clusters,
which shared similar smoking history were found. Cluster 1 included men with moderate airway
obstruction (n¼ 67) while cluster 2 comprised men who were exacerbation-prone, with severe air-
flow limitation and intense granulocytic airway and neutrophilic systemic inflammation (n¼ 56).
Cluster 3 essentially included women with moderate airway obstruction (n¼ 55). All clusters had a
low rate of bacterial colonization (5%), a low median FeNO value (<20ppb) and a very low sensi-
tization rate toward common aeroallergens (0-5%). CAT score did not differ between clusters.
Including markers of systemic airway inflammation and atopy and applying a comprehensive clus-
ter analysis we provide here evidence for 3 clusters markedly shaped by sex, airway obstruction
and neutrophilic inflammation but not by symptoms and T2 biomarkers.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
and heterogeneous disease with a large number of subtypes
and a multifactorial background [1, 2]. It may be caused by
different pathophysiologic mechanisms (sometimes referred to
as endotypes) but may share similar observed characteristics
(phenotypes) [3]. These phenotypes divide all patients into sev-
eral groups with common features that help patients to receive
effective care and achieve better clinical results.
Within the data mining framework one of the most rec-
ognized methods for discovering knowledge in multivariate
dataset, is clustering. Cluster analysis attempt to find groups
of patients such that patients in the same cluster are more
similar to each other than to patients in another cluster [4].
In recent years, cluster analysis was applied as a popular
method to examine heterogeneity of patients with asthma
[5, 6] or COPD [7–12]. Within the clustering framework,
missing values, which are present in such large datasets, and
how to handle it have not been referred among different
studies [13]. As different analysis methods exist with their
own criterion for clustering and determination of the
number of clusters, hierarchical and nonhierarchical, differ-
ent results are proposed. Another key point is number of
variables in clustering, how select them and this fact that
correlation exists between initially selected variables, the
strategies of data transformation using principal component
analysis solved this point [9, 10, 14–17].
In this paper, we introduce a flexible framework for clus-
ter analysis on multidimensional dataset, which handles
missing value by multiple imputation. COPD clustering
studies have brought insight to the importance of co-mor-
bidities and systemic inflammation as components account-
ing for disease variability [18]. There are studies that used
demographic variables, symptoms, spirometry, imaging and
comorbidities to build the clusters [19]. However, there are
not many studies using clustering that investigated the air-
way inflammatory component and the atopic status in large
cohort of COPD. As it is recognized that some COPD may
express T2 biomarkers [20], we included serum IgE and
FeNO in our standard routine investigation of COPD in
order to see whether the T2 trait is frequent and strong
enough to shape a cluster in a population of COPD denying
any existence of asthma before the age of 40 years.
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Here we performed clustering analysis on a cohort of 178
COPD patients recruited from ambulatory care in whom detailed
lung function, blood and sputum analysis were available.
Material and methods
The retrospective study was conducted on 178 stable COPD
patients recruited from ambulatory care in our COPD clinic
in the Pneumology Department of the University hospital of
Liege. We have a general agreement from the ethics com-
mittee to use clinical data collected from routine practice to
make retrospective reports. The protocol was approved by
the Hospitalo-Facultaire Universitaire ethics committee,
Liege (institutional review board 2005/181). Every patient
attending ambulatory clinic care signs an informed consent
stating that they accept this principle. Selection criteria to be
referred to our COPD clinic were symptomatic patients
(including at least one of the three following symptoms: dys-
pnea, cough and sputum production) with FEV1/FVC ratio
post bronchodilation less than 70%, age above 40 years and
smoking history of at least 20 pack years. None had an
asthma history starting before the age of 40. At the COPD
clinic the patients had systematic pre and post bronchodila-
tion spirometry, sputum induction, blood sampling, and
completed the self-administered CAT questionnaire. From
the clinical data, a comprehensive list of 84 variables was
derived and divided into six categories, i.e. demographics,
pulmonary function tests, treatment features, blood cell
counts and systemic inflammatory markers, atopic status,
and sputum cell counts and microbiology. One unavoidable
problem in huge dataset is the presence of missing value.
The percentage of missing values ranged from 0% to 23%
and 75% of patients presented at least one missing value.
This matter creates serious problems as most of the classical
statistical methods are not designed to handle incomplete
data. By default, in statistical methods and software, patients
with at least one missing value are discarded from the ana-
lysis. In practical research, multiple imputation is a popular
and very flexible technique for handling missing value [21].
Multiple imputation replaces each missing value with a set
of m (>1) plausible values. Therefore, instead of one incom-
plete dataset, multiple imputation provides m separate com-
plete datasets [22]. In the present study, m was fixed to 100.
Then, 100 imputed datasets are analyzed by the method that
would have been appropriate if the data had been complete.
The derived results from the analyses are then combined to
produce the final quantity of interest following Rubin’s rules
[23]. The number of variables is an important issue in clus-
ter analysis specially in determining the number of clusters.
Indeed, large number of variables result in poor discrimin-
ation distance and misspecification classification. Therefore,
in this study with huge numbers of variables, the percentage
of contribution of variables was determined, and then, the
strategy of variable reduction was applied. Cluster analysis is
a powerful but unsupervised method. The big issue in this
unsupervised method is, to evaluate the quality of the clus-
tering framework for classification. Clustering validation was
considered to evaluate this issue. Statistical methodology is
discussed in the online supplement in more detail.
Statistical method
Quantitative variables were summarized using median and
interquartile range (P25 - P75); while count and percentage
were used for qualitative variables. Outlines of the proposed
steps to assign clustering for patients are described in Table
1. Missing values were imputed by draw from the posterior
predictive distribution of bayesian model and predictive
mean matching (PMM) was used as a robust method to
model misspecification in imputing values. Since this study
contains quantitative and qualitative variables, factor analysis
for mixed data (FAMD) was applied for creating new com-
ponents. In cluster analysis step, the number of clusters for
each imputed dataset was determined by hierarchical cluster-
ing and a package of 30 indices for determining the relevant
number of clusters, then K-means was applied for assigning
clusters to patients. In consensus step, final clustering result
was achieved by minimizing the sum of squared distance of
existing clustering results. For each clustering output, two
indices for internal clustering validation and stability valid-
ation were calculated. Output of consensus clustering was
considered as the individual final clustering result for raw
and all of imputed datasets. Then, median and interquartile
range were calculated for all variables in raw dataset and for
each imputed dataset. Finally, an overall median with corre-
sponding interquartile range was calculated over all 100
imputed datasets. All variables were compared between the
derived clusters using Kruskal-Wallis and Chi-squared tests
for quantitative and qualitative variables, respectively.
Comparison among clusters was applied according to
Dunn’s multiple comparison test. Finally, the difference
between three groups was displayed by boxplot. All analyses
were performed using R statistical software. P values <0.05
were considered as statistically significant.
Table 1. Process of factor analysis and cluster analysis to describe phenotypes
in COPD.
(1) Multiple imputation
i) Obtain 100 complete dataset by multiple imputation (MICE)
(2) Factor analysis for mixed data (FAMD)
i) Determine quantitative and qualitative variable
ii) Apply FAMD for each imputed dataset
iii) Determine the number of components for each imputed dataset
(3) Hierarchical clustering
i) Choosing the best number of clusters for each imputed dataset
(4) Partitioning Clustering
i) Consider the number of clusters in previous step
ii) Assign patients to each cluster for each imputed dataset by
partitioning clustering
(5) Consensus clustering
i) Combine all ensemble clustering to get a final best clustering
(6) Assign patients to the final result of consensus clustering
i) Allocate patients in raw dataset (dataset with missing value) and each
imputed dataset to calculate final result of consensus clustering
(7) Description of clustering
i) Calculate median for raw dataset and overall median for imputed datasets
ii) Comparison between cluster (Kruskal-Wallis and Chi-squared tests and
Dunns multiple comparison test)
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Table 2. Characteristics of the COPD cohort.
Variable Median (IQR)/percentage (frequency) Percentage (number) of missing value
Demographic Age (year) 64.5(57–72) 0% (0)
Sex (Male) 54.49% (97) 0% (0)
Height (cm) 167(160–175) 0.56% (1)
Weight (kg) 67(58–78) 0.56% (1)
BMI (kg/m2) 23.62 (21.22–27.18) 0.56% (1)
Cigarette Packs (year) 37.2 (22.5–50) 2.25% (4)
Cigarettes (day) 20 (10–23.5) 3.93% (7)
Smoking Duration(year) 43 (33–50) 2.8% (5)
OCS Course 0 60.71% (102)
1 23.81% (40) 5.62% (10)
2 15.48% (26)
Antibiotic Course 0 36.47% (62) 4.49% (8)
1 51.76% (88)
2 11.76% (20)
Emergency Room Admission for asthma or COPD 0 84.66% (149) 1.12% (2)
1 14.77% (26)
2 0.57% (1)
Number of hospitalizations for asthma or COPD 0 85.55% (148) 2.8% (5)
1 12.72% (22)
2 1.73% (3)
Pulmonary FeNO (ppb) 16 (10–25) 7.30% (13)
FEV1 (mL) 1380 (1085–1810) 0% (0)
FEV1 predicted (%) 53 (43–66) 0% (0)
FEV1 PD (mL) 1480 (1180–1930) 0.56% (1)
FEV1 PD predicted (%) 57 (47–71) 0.56% (1)
Reversibility (%) 7 (1–12) 0.56% (1)
FVC (mL) 2505 (2020–3067.5) 0% (0)
FVC predicted (%) 77 (64–89) 0% (0)
FVC post (mL) 2580 (2080–3200) 0.56% (1)
FVC post (%) 80 (68–92) 0.56% (1)
FEV1/ FVC pre (%) 56.4 (48.12–64.27) 0% (0)
FEV1/ FVC post (%) 57.9 (49.4–66.5) 0.56% (1)
TLC (L) 6.45 (5.37–7.17) 16.29% (29)
TLC predicted (%) 109 (96–123) 16.29% (29)
RV (L) 3.58 (3.07–4.55) 16.29% (29)
RV predicted (%) 168 (137–201) 16.29% (29)
RV/TLC (%) 59.58 (52.79–66.21) 16.29% (29)
DLCO (mmol/kPa.min) 3.98 (2.91–5.3) 17.41% (31)
DLCO predicted (%) 49 (37.5–60) 17.41% (31)
DLCO/VA 0.93 (0.71–1.16) 17.41% (31)
DLCO/VApredicted (%) 67 (50–81.5) 17.41% (31)
sGaw (1/kPasec) 0.47 (0.34–0.71) 23.03% (41)
FRC (L) 4.91 (4.09–5.89) 21.34% (38)
FRC predicted (%) 158 (138–183) 21.34% (38)
Treatment Treatment (Yes) 61.76% (105) 4.49% (8)
ICS (Yes) 55.11% (97) 1.12% (2)
OCS (Yes) 5.11% (9) 1.12% (2)
LAMA (Yes) 51.13% (90) 1.12% (2)
LABA (Yes) 67.04% (118) 1.12% (2)
SABA (Yes) 40.91% (72) 1.12% (2)
LTRA (Yes) 3.41% (6) 1.12% (2)
Theophylline (Yes) 2.84% (5) 1.12% (2)
CAT score 25 (16–31) 0% (0)
Blood Leucocytes (mL) 7.97 (6.67–9.73) 7.86% (14)
Neutrophils (%) 60.7 (54–67.75) 8.43% (15)
Lymphocytes (%) 27.8 (21.35–34.3) 8.43% (15)
Monocytes (%) 7.9 (6.55–9.45) 8.43% (15)
Eosinophils (%) 2 (1–3.25) 8.43% (15)
Basophils (%) 0.4 (0.3–0.6) 8.43% (15)
Neutrophils (mL) 4840.71 (3782.47–6027.27) 8.43% (15)
Lymphocytes (mL) 2213.4 (1739.08–2710.78) 8.43% (15)
Monocytes (mL) 646.99 (496.08–836.3) 8.43% (15)
Eosinophils (mL) 147.63 (77.46–252.0) 8.43% (15)
Basophils (mL) 31.24 (21.37–48.3) 8.43% (15)
Fibrinogen (g/l) 3.52 (2.96–4.02) 4.49% (8)
CRP (mg/l) 2.45 (1.10–5.75) 4.49% (8)
Alpha 1 antitrypsin (g/l) 1.5 (1.36–1.68) 12.36% (22)
Calcium (mmol/L) 2.42 (2.36–2.47) 6.74% (12)
25(OH) Vitamine D (ng/ml) 20 (12–30.97) 13.48% (24)
Phosphate (mmol/L) 0.93 (0.79–1.06) 6.74% (12)
Atopy IgE (KU/L) 72.50 (22.75–227.75) 10.11% (18)
RAST DPT (d1) %>0.35 (KU/L) 11.39% (18) 11.24% (20)
RAST Cat (e1), %>0.35 (KU/L) 3.75% (6) 10.11% (18)
RAST Dog (e5), %>0.35 (KU/L) 3.12% (5) 10.11% (18)
(continued)
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Results
Characteristics of the total patients and percentage of miss-
ing values before imputing are presented in Table 2. Patients
were mostly males (54.49%) with age ranging from 40 to
84 years and displayed a normal weight (median body mass
index was 23.62). Patients had a consistent tobacco con-
sumption history with a median pack/year of 37.
Table 3 shows the order and the impact of each variable
on clustering. The highest contribution for variables in clus-
tering is for FEV1 (mL), FEV1 PD (mL), FEV1 PD pre-
dicted (%), FEV1 predicted (%) and FVC (mL) (Figure 1).
Based on all operational processes indicated in Table 1,
three distinct clusters with acceptable values for validation
were identified weighing similarly regarding the number of
patients from this procedure for COPD dataset and output
for 100 imputed datasets displayed in Table 4. In this study,
two indices for internal clustering validation and two indices
for clustering stability validation are reported. Silhouette
Width and Dunn Index values for Internal measures are
0.61 and 0.54, respectively. Average Proportion of Non-over-
lap and Average Distance between Means for Stability meas-
ures are 0.02 and 0.01, respectively (For more information,
refer to supplementary, clustering validation). There were
striking sex differences between the clusters with a clear
dominance of male in clusters 1 and 2 while cluster 3 was
essentially composed of women. Smoking history was similar
between clusters and BMI was slightly higher in cluster 1
while still remaining in the normal range. Clusters 2 and 3
received more often courses of OCS the year prior to the
visit whereas there was no difference regarding the number
of antibiotic course. Clusters 2 and 3 were those in which
patients received more maintenance treatment including
ICS, LAMA, LABA and also used more often SABA as
reliever. Cluster 2 and 3 had also more impaired lung func-
tion with more severe airway obstruction, lung hyperdisten-
sion and severely reduced diffusing capacity and transfer
coefficient (Figure 2). As far as inflammation is concerned,
the cluster 2 had more severe systemic and airway neutro-
philic inflammation, with slightly raised fibrinogen but not
CRP. Circulating lymphocytes were reduced in cluster 2
(Figures 3 and 4). Absolute sputum eosinophil counts were
higher in cluster 2 than in cluster 1 while no difference was
seen in blood (Figure 5). FeNO levels were similar between
clusters and no difference was seen regarding total serum
IgE (Figure 5) nor sensitizations to aeroallergens, which
were rare in all three clusters. Interestingly, CAT score did
not differ between the three clusters despite clear differences
in lung function impairment (Figure 6).
Discussion
In this study, we characterized COPD patients into three
distinctly different groups by applying general and flexible
statistical computation in dataset with missing values. In the
present study, clustering was applied to a large number of
variables instead of selecting a limited number of variables.
Although missing values are a common and pervasive prob-
lem in diverse datasets such as COPD with large number of
variables, missing values have not been considered property
in the clustering literature. Based on these restrictions, clas-
sification on COPD datasets has not been comprehensively
investigated. Therefore, in this exhaustive study, phenotypes
in COPD dataset were described by imputing missing val-
ues, principal components and cluster analysis with many
analytical decisions, which overcome limitations, often
reported in previous clustering studies.
The concept of treatable trait has become very popular
over the last years and it has been suggested to avoid label
of asthma or COPD among patients with severe chronic air-
way diseases [24]. Adopting this taxonomic view our COPD
population could be seen as a population featuring the trait
of fixed airway obstruction after a significant smoking his-
tory and denying any previous diagnosis of asthma before
the age of 40. One strength of our study, compared to previ-
ous clustering analysis in COPD, is that it included airway
inflammatory features, FeNO and atopic status in the
parameters subjected to analysis.
We actually found 3 clusters of COPD, strikingly linked
to sex with two clusters showing male dominance while the
third was essentially a female cluster. There were clear dif-
ferences between lung function impairment between the
clusters whereas quantitative smoking history was quite
Table 2. Continued.
Variable Median (IQR)/percentage (frequency) Percentage (number) of missing value
RAST Grass (GX3), %>0.35 (KU/L) 6.96% (11) 11.24% (20)
RAST microog (MIX1), %>0.35 (KU/L) 9.37% (15) 10.11% (18)
RAST Birch (t3), %>0.35 (KU/L) 1.25% (2) 10.67% (19)
Sputum Positive Aerobic Sputum Culture 8.96% (13) 18.54% (33)
Weight of sputum (g) 1.72 (1.1–2.98) 20.78% (37)
Total Cell Counts (106/g) 2.31 (0.98–5.6) 20.78% (37)
Squamous (%) 10 (3–33) 20.78% (37)
Viability (%) 69 (55–84) 20.78% (37)
Macrophages (%) 12.3 (5–23.6) 21.91% (39)
Lymphocytes (%) 1 (0–2) 21.91% (39)
Neutrophils (%) 74.8 (56.87–91.05) 21.34% (38)
Eosinophils (%) 1.35 (0.2–4.40) 21.34% (38)
Epithelial cells (%) 2.5 (0.6–7.75) 21.91% (39)
Macrophages (103/g) 268.28 (80.04–583.8) 23.03% (41)
Lymphocytes (103/g) 18.48 (0–43.8) 23.03% (41)
Neutrophils (103/g) 1307.5 (503.89–3831.61) 22.47% (40)
Eosinophils (103/g) 28.86 (2.77–232.69) 22.47% (40)
Epithelial cells (103/g) 55.4 (11.25–202.86) 22.47% (40)
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similar, pointing to different susceptibility to tobacco among
patients. The percentage of contribution of the different var-
iables to the clustering. It appears that functional criteria
including airway flow and the degree of airway obstruction
and lung hyperdistension and the % of blood lymphocytes
are amongst the most important criteria to structure the
cluster while variables like smoking history, FeNO and
Vitamin D level were rather homogeneous between
the subjects.
The cluster 2 is conspicuously the most severe group of
patients with marked airway obstruction, lung hyperdisten-
sion capacity together with intense neutrophilic inflamma-
tion both at the systemic and the airway level, in keeping
with the previously reported relationship between the sever-
ity of airway obstruction and the neutrophilic inflammation
[25]. Cluster 2 and 3 had also impaired diffusing capacity
and transfer coefficient pointing to emphysema. Despite
severe emphysema the level of a1- antitrypsin was higher in
cluster 2, perhaps indicating a response of the body trying
to counteract the lung destruction favored by the intense
neutrophilic inflammation.
Associated with neutrophilic inflammation, cluster 2, dis-
plays a small rise in fibrinogen level even through the
median value remained within the normal range and below
the threshold of 5.1 g/l, shown to be predictive of an excess
of mortality [26]. Of note is the fact that the intensity in
neutrophilic airway inflammation is not associated with bac-
terial colonization identified by classical bacterial culture,
which was rather low come close to 10% for the whole
cohort. Of course, it does not imply that microbiome may
be profoundly disturbed in COPD and more sophisticated
microbiological analyses might have revealed differences
between the clusters. Altered microbiome may be the conse-
quence of frequent antibiotic courses received by the
patients as shown in our cohort since almost two third of
the patients had received antibiotics for bronchitis the year
prior the visit. It is worth noting that there was no differ-
ence between clusters in the number of antibiotic courses.
As opposed to exacerbation defined by OCS course, exacer-
bation defined by antibiotic course was not related the
severity of lung function impairment nor to the severity of
airway inflammation.
Table 3. Percentage of the contribution of variables in clustering.




1 FEV1 (mL) 0.795354
2 FEV1 PD (mL) 0.792187
3 FEV1 PD predicted (%) 0.708569
4 FEV1 predicted (%) 0.696766
5 FVC (mL) 0.510238
6 FVC post (mL) 0.49998
7 FVC predicted (%) 0.488792
8 FVC post (%) 0.488091
9 RV/TLC (%) 0.373624
10 FEV1/ FVC post (%) 0.318253
11 DLCO (mmol/kPa.min) 0.290582
12 Emergency Room Admission
for asthma or COPD
0.290175
13 FEV1/ FVC pre (%) 0.283042
14 Blood_Neutrophils (%) 0.207177
15 Blood_Lymphocytes (%) 0.185377
16 DLCO predicted (%) 0.167944
17 sGaw (1/kPasec) 0.166534
18 LAMA (Yes) 0.162801
19 LABA (Yes) 0.161971
20 ICS (Yes) 0.159877
21 Blood_Neutrophils (mL) 0.14896
22 Treatment (Yes) 0.148225
23 RV predicted (%) 0.143311
24 Number of hospitalizations for asthma or COPD 0.132193
25 FRC predicted (%) 0.12998
26 Weight (kg) 0.115709
27 OCS Course 0.099888
28 RV (L) 0.092256
29 Height (cm) 0.08524
30 Blood_Lymphocytes (mL) 0.076047
31 DLCO/VA 0.073329
32 BMI (kg/m2) 0.067138
33 DLCO/VApredicted (%) 0.066027
34 Blood_Leucocytes (mL) 0.064596
35 CAT score 0.062324
36 OCS (Yes) 0.061563
37 Blood_Monocytes (%) 0.060734
38 Total Cell Counts (106/g) 0.060281
39 Alpha 1 antitrypsin (g/l) 0.059218
40 Fibrinogen (g/l) 0.057644
41 TLC predicted (%) 0.054684
42 Viability (%) 0.052038
43 Sputum_Eosinophils (103/g) 0.051767
44 SABA (Yes) 0.046993
45 Antibiotic Course 0.045641
46 Age (year) 0.044547
47 Weight of sputum (g) 0.042916
48 Sputum_Neutrophils (103/g) 0.04283
49 Sex (Male) 0.040351
50 Sputum_Lymphocytes (103/g) 0.035228
51 Theophylline (Yes) 0.034857
52 Smoking Duration(year) 0.030539
53 CRP (mg/l) 0.030115
54 FRC (L) 0.028202
55 Positive Aerobic Sputum Culture 0.027121
56 Blood_Eosinophils (%) 0.024198
57 RAST Grass (GX3), %>0.35 (KU/L) 0.020597
58 Sputum_Neutrophils (%) 0.01398
59 Positive Aerobic Sputum Culture 0.013011
60 IgE (KU/L) 0.010926
61 25(OH) Vitamine D (ng/ml) 0.00967
62 Blood_Basophils (%) 0.008521
63 FeNO (ppb) 0.008171
64 RAST Birch (t3), %>0.35 (KU/L) 0.007232
65 Squamous (%) 0.007092
66 Sputum_Epithelial cells (%) 0.005941
67 TLC (L) 0.005787
68 Sputum_Eosinophils (%) 0.00525
69 Cigarettes (day) 0.005246
70 Blood_Monocytes (mL) 0.004464
71 RAST DPT (d1) %>0.35 (KU/L) 0.002943
(continued)
Table 3. Continued.




72 Sputum_Lymphocytes (%) 0.002614
73 RAST microog (MIX1), %>0.35 (KU/L) 0.002255
74 Sputum_Macrophages (103/g) 0.001858
75 Phosphate (mmol/L) 0.001491
76 RAST Cat (e1), %>0.35 (KU/L) 0.001486
77 LTRA (Yes) 0.001457
78 Sputum_Macrophages (%) 0.001438
79 Blood_Basophils (mL) 0.001318
80 RAST Dog (e5), %>0.35 (KU/L) 0.001291
81 Calcium (mmol/L) 0.001184
82 Blood_Eosinophils (mL) 0.000887
83 Reversibility (%) 0.00079
84 Cigarette Packs (year) 0.00077
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Table 4. Characteristics of patients with COPD after imputation, Median (IQR) / Percentage (frequency) in each cluster and comparison between clusters.
Variable
Result for clustering on 100 imputed datasets
Cluster 1 (n¼ 67) Cluster 2 (n¼ 56) Cluster 3 (n¼ 55) P-value
Demographic Age (year) 62(55–66)a 67(60.75–74.25)b 67(58.5–73)bþ <0.001
Sex (Male) 76.12%(51)a 75%(42)a 7.27%(4)b <0.0001
Height (cm) 173(166.5–178)a 169.5(162–17.25)a 161(156–165)b <0.0001
Weight (kg) 77(65–89)a 67(56.75–76)b 60(53–66)c <0.0001
BMI (kg/m2) 25.59(22.34–30.21)a 23.08(20.55–24.89)b 23.15(19.89–25.55)b <0.001
Cigarette Packs (year) 36.9(21.52–50)a 42.5(24.62–52.5)a 34.5(21.42–43.87)a >0.05
Cigarettes (day) 20(10–25)a 20(10–21.25)a 20(10–20)a >0.05
Smoking Duration(year) 40(31–46)a 46.5(34.25–52.25)b 44(37–50)b <0.05
OCS Course 0 80.59%(54) a 30.35%(17) b 61.82%(34) a <0.0001
1 13.43%(9) 32.14%(18) 23.64%(13)
2 4.48%(3) 35.71%(20) 10.91%(6)
Antibiotic Course 0 43.28%(29) a 32.14%(18) a 32.73%(18) a >0.05
1 46.27%(31) 50%(28) 58.18%(32)
2 8.95%(6) 16.07%(9) 10.91%(6)
Emergency Room Admission
for asthma or COPD
0 95.52%(64) a 71.43%(40) b 85.45%(47) a <0.0001
1 4.48%(3) 26.78%(15) 14.54%(8)
2 0%(0) 1.78%(1) 0%(0)
Number of hospitalizations
for asthma or COPD
0 97.01%(65) a 67.86%(38) b 89.09%(49) a <0.0001
1 2.98%(2) 26.78%(15) 10.91%(6)
2 0%(0) 5.36%(3) 0%(0)
Pulmonary FeNO (ppb) 15(10.5–23)a 18.5(10–30.5)a 14(8–25.5)a >0.05
FEV1 (mL) 1950(1700–2205)a 1085(780–1352.5)b 1240(1075–1390)b <0.0001
FEV1 predicted (%) 66(56–78)a 37(30–45.25)b 55(47.5–66)c <0.0001
FEV1 PD (mL) 2000(1820–2405)a 1190(837.5–1380)b 1310(1135–1470)b <0.0001
FEV1 PD (%) 69(60.5–81.5)a 40(32.75–50)b 59(51.5–69.5)c <0.0001
Reversibility (%) 7(1–10.5)a 6.5(1–11.25)a 8(2–13.5)a >0.05
FVC (mL) 3200(2625–3780)a 2427.5(1705–2767.5)b 2140(1820–2390)c <0.0001
FVC predicted (%) 86(74–99.5)a 65(55.75–74.25)b 77(68.5–85.5)c <0.0001
FVC post (mL) 3320(2805–3870)a 2385(1797.5–2900)b 2130(1870–2445)c <0.0001
FVC post (%) 90(79.5–101)a 68(56.75–76.5)b 80(71.5–91.5)c <0.0001
FEV1/ FVC pre (%) 63.1(56.45–66.65)a 47(40.37–50.42)b 57.1(53.15–64.5)a <0.0001
FEV1/ FVC post (%) 64(58.3–68.55)a 47.5(42.8–53.2)b 59.9(54.5–67.05)a <0.0001
TLC (mL) 6725(5725–7385)a 6830(5847.5–8107.5)a 5440(4975–6005)b <0.0001
TLC predicted (%) 103(93–112)a 113(100.75–125.25)b 115(102–127.5)b <0.001
RV (mL) 3320(2970–3820)a 4515(3690–5277.5)b 3270(2920–3725)a <0.0001
RV (%) 141(128–171.5)a 183.5(163.87–228.5)b 172(148.5–193.25)c <0.0001
RV/TLC (%) 52.99(46.71–57.18)a 66.37(61.28–69.14)b 60.84(57.03–64.06)c <0.0001
DLCO (mmol/kPa.min) 5.2(4.06–5.88)a 3.47(2.67–4.44)b 3.27(2.69–4.03)b <0.0001
DLCO predicted (%) 57(46.5–67)a 41.5(30.75–58)b 45(37.5–53.5)b <0.0001
DLCO/VA 1.03(0.79–1.28)a 0.80(0.63–0.99)b 0.93(0.71–1.15)b <0.0001
DLCO/VA predicted (%) 70(57–88)a 59.5(45.75–79)b 60(50–77.5)b <0.001
sGaw (1/kPasec) 0.65(0.44–0.88)a 0.35(0.24–0.45)b 0.47(0.34–0.73)c <0.0001
FRC (L) 4.83(4.08–5.43)a 5.87(4.82–6.49)b 4.24(3.77–4.95)c <0.0001
FRC predicted (%) 143(122–161)a 174(154.75–192)b 160.5(141.5–180.5)c <0.0001
Treatment Treatment (Yes) 44.78%(30)a 78.57%(44)b 67.27%(37)b <0.0001
ICS (Yes) 29.85%(20)a 71.43%(40)b 69.10%(38)b <0.0001
OCS (Yes) 1.49%(1)a 16.07%(9)b 0%(0)a <0.0001
LAMA (Yes) 34.33%(23)a 73.21%(41)b 49.09%(27)a <0.0001
LABA (Yes) 44.78%(30)a 82.14%(46)b 76.36%(42)a <0.0001
SABA (Yes) 25.37%(17)a 50%(28)b 49.09%(27)b <0.001
LTRA (Yes) 2.98%(2)a 0%(0)a 7.27%(4)a >0.05
Theophylline (Yes) 1.49%(1)a 5.36%(3)a 1.82%(1)a >0.05
CAT score 22(15–31)a 26(19–30)a 24(17–30)a >0.05
Blood Leucocytes (mL) 7.71(6.52–9.43)a 8.56(6.87–11.10)a 7.81(6.64–9.2)a >0.05
Neutrophils (%) 58.2(52.75–63.55)a 67.6(60.1–73.22)b 58.3(53.25–64.85)a <0.0001
Lymphocytes (%) 30.3(25.65–35)a 20.95(15.7–27.27)b 29(23.82–35.12)a <0.0001
Monocytes (%) 8.7(7.1–9.8)a 7.8(6.34–9.82)b 7.1(6.4–8.67)b <0.05
Eosinophils (%) 2(1.1–3.25)a 1.9(0.9–3.22)a 2.1(0.95–3.35)a >0.05
Basophils (%) 0.4(0.3–0.6)a 0.3(0.2–0.5)a 0.4(0.3–0.7)a >0.05
Neutrophils (mL) 4529.13(3723.5–5501.7)a 5574.91(4097.7–7842.7)b 4840.71(3393.7–5743.1)a <0.05
Lymphocytes (mL) 2346.8(1844.6–2968.1)a 1847.22(1340.4–2382.2)b 2253.3(1846.6–2710.8)a <0.0001
Monocytes (mL) 668.82(507.24–831.28)a 652.58(511.72–864.82)a 605.82(485.32–748.05)a >0.05
Eosinophils (mL) 138(75.12–240.24)a 168.78(69.23–258.42)a 147.63(88.26–255.97)a >0.05
Basophils (mL) 30.84(21.48–42.58)a 27.63(18.88–46.25)a 32.04(23.95–48.97)a >0.05
Fibrinogen (g/l) 3.43(2.88–3.86)a 3.65(3.08–4.50)b 3.54(2.98–3.80)b <0.05
CRP (mg/l) 2.3(1.25–4.95)a 2.9(0.87–7.7)a 1.8(1–4.75)a >0.05
Alpha 1 antitrypsin (g/l) 1.49(1.34–1.57)a 1.61(1.39–1.76)b 1.49(1.35–1.64)a <0.05
Calcium (mmol/L) 2.42(2.37–2.47)a 2.41(2.35–2.48)a 2.44(2.38–2.47)a >0.05
25(OH) Vitamine D (ng/ml) 18(12–30.9)a 17.5(10–26.75)a 24(15.5–33)a >0.05
Phosphate (mmol/L) 0.89(0.77–0.95)a 0.88(0.72–1.06)a 1.01(0.93–1.11)b <0.0001
Atopy IgE (KU/L) 52(23–184.5)a 91.5(28.75–304.75)a 73(21–170)a >0.05
RAST DPT (d1) %>0.35 (KU/L) 13.43%(9)a 16.07%(9)a 7.27%(4)a >0.05
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We also looked at phosphocalcic metabolism and found,
as expected in western Europe, reduced levels of 25 OH Vit
D (< 30 ng/ml) in all clusters without any difference
between the groups. While Calcium levels, a tightly regu-
lated ion, were normal and similar between the three clus-
ters, there were striking differences in the levels of
phosphates, which were clearly lower in cluster 1 and 2. The
literature about phosphate level in COPD is virtually absent
and the clinical meaning of our finding remains obscure
though there might be a sex effect as this demographic trait
best differentiates cluster 1 and 2 from cluster 3.
Eosinophilic trait is a marker of response to corticoids in
asthma but also in COPD. In our study, blood eosinophilic
inflammation does not appear to be discriminant feature
between the clusters but cluster 2 shows a greater absolute,
but not relative, sputum eosinophil cell count. However, the
three clusters had median value of sputum eosinophil counts
greater than that we found in a healthy population [27] and,
Table 4. Continued.
Variable
Result for clustering on 100 imputed datasets
Cluster 1 (n¼ 67) Cluster 2 (n¼ 56) Cluster 3 (n¼ 55) P-value
RAST Cat (e1), %>0.35 (KU/L) 1.49%(1)a 7.14%(4)a 1.82%(1)a >0.05
RAST Dog (e5), %>0.35 (KU/L) 2.98%(2)a 5.36%(3)a 0%(0)a >0.05
RAST Grass (GX3), %>0.35 (KU/L) 5.97%(4)a 14.28%(8)a 1.82%(1)a >0.05
RAST microog (MIX1),%>0.35 (KU/L) 7.46%(5)a 12.5%(7)a 10.91%(6)a >0.05
RAST Birch (t3), %>0.35 (KU/L) 0%(0)a 3.57%(2)a 0%(0)a >0.05
Sputum Positive Aerobic Sputum Culture 8.95%(6)a 16.07%(9)a 12.73%(7)a >0.05
Weight of sputum (g) 1.77(1.28–3.01)a 1.45(0.97–3.05)a 1.65(0.93–3.28)a >0.05
Total Cell Counts (106/g) 1.70(0.90–4.41)a 4.90(1.58–15.96)b 2.65(1.08–5.43)a <0.05
Squamous (%) 19(6–42)a 7(2–31.12)b 9.5(2–23.5)b <0.05
Viability (%) 68(53.5–85.5)a 69(51–86)a 67(48.5–79.5)a >0.05
Macrophages (%) 14(6.7–26.1)a 6.5(2.54–15.15)b 17(7–29.95)a <0.0001
Lymphocytes (%) 1.2(0–2.3)a 0.6(0.15–1.5)a 1.2(0–3)a >0.05
Neutrophils (%) 71.4(56.35–88.2)a 78.9(58.8–92.19)a 60.4(39.3–81.05)b <0.001
Eosinophils (%) 1.4(0.2–4.92)a 2.3(0.2–9.12)a 2(0.7–9.15)a >0.05
Epithelial cells (%) 2.4(0.4–8.1)a 3.25(0.57–11.05)a 4.7(1.3–15.2)a >0.05
Macrophages (103/g) 233.55(53.28–691.65)a 301.29(31.37–755.45)a 330.48(58.13–816.67)a >0.05
Lymphocytes (103/g) 14.2(0–43.07)a 23.75(4.39–63.9)a 25.2(3.42–72.5)a >0.05
Neutrophils (103/g) 1090(490.86–2339.64)a 2482.84(883.9–11720.8)b 1110(493.04–3483.82)a <0.05
Eosinophils (103/g) 19.92(0–166.96)a 71.67(0–638.26)b 33.04(5.65–293.7)a <0.001
Epithelial cells (103/g) 38.45(5.66–142.29)a 94(18.07–292.65)a 81.36(16.4–301.24)a >0.05
þThere are no significant differences between two clusters with the same letter.
Figure 1. Percentage of the contribution of variables in clustering.
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actually, rather similar to what is found in large popula-
tion of unselected asthmatics [28]. Furthermore, the
greater amount of eosinophils present in sputum of
COPD was noted despite heavier treatment with ICS in
this cluster, which points to some corticoresistance in
this cluster.
Atopic status based on positive RAST toward aeroaller-
gens was low in the three clusters but total serum IgE was
Figure 2. Lung function in three clusters.
Figure 3. Blood in three clusters.
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Figure 4. Sputum in three clusters.
Figure 5. T2 biomarkers in three clusters.
Figure 6. Cat Score in three clusters.
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Table 5. Characteristics of patients with COPD before imputation, Median (IQR) / Percentage (frequency) in each cluster and comparison between clusters.
Variable
Result for clustering on raw dataset
P-valueCluster 1 Cluster 2 Cluster 3
Demographic Age (year) 62(55–66)b 67(60.75–74.25)a 67(58.5–73)a <0.001
Sex (Male) 76.12%(51[67])a 75%(42[56])a 7.27%(4[55])b <0.0001
Height (cm) 174(167–178)a 169.5(162–175.25)a 161(156–165)b <0.0001
Weight (kg) 77(65–89)c 67(56.75–76)a 60(53–66)b <0.0001
BMI (kg/m2) 25.59(22.21–30.21)b 23.08(20.56–24.89)a 23.15(19.89–25.55)a <0.001
Cigarette Packs (year) 36.9(21–50)a 42.5(23.25–52.5)a 35(22.05–43.87)a >0.05
Cigarettes (day) 20(10–25)a 20(10–21.25)a 20(10–20)a >0.05
Smoking Duration(year) 40(32–46.5)c 47(34.25–52.25)a 44(37–50)ab <0.05
OCS Course 0 81.25%(52[64]) b 31.37%(16[51]) a 64.15%(34[53]) b <0.0001
1 14.06%(9[64]) 35.29%(18[51]) 24.53%(13[53])
2 4.69%(3[64]) 33.33%(17[51]) 11.32%(6[53])
Antibiotic Course 0 42.86%(27[63]) a 32.07%(17[53]) a 33.33%(18[54]) a >0.05
1 47.62%(30[63]) 50.94%(27[53]) 57.41%(31[54])
2 9.52%(6[63]) 16.98%(9[53]) 9.26%(5[54])
Emergency Room Admission
for asthma or COPD
0 95.45%(63[66]) b 70.91%(39[55]) a 85.45%(47[55]) b <0.0001
1 4.54%(3[66]) 27.27%(15[55]) 14.54%(8[55])
2 0%(0[66]) 1.82%(1[55]) 0%(0[55])
Number of hospitalizations
for asthma or COPD
0 96.97%(64[66]) b 67.92%(36[53]) a 88.89%(48[54]) b <0.0001
1 3.03%(2[66]) 26.41%(14[53]) 11.11%(6[54])
2 0%(0[66]) 1.89%(1[53]) 0%(0[54])
Pulmonary FeNO (ppb) 15(10.5–23)a 19(10–32.25)a 15(8–24)a >0.05
FEV (mL) 1950(1700–2205)b 1085(780–1352.5)a 1240(1075–1390)a <0.0001
FEV1 predicted (%) 66(56–78)c 37(30–45.25)a 55(47.5–66)b <0.0001
FEV1 PD (mL) 2000(1820–2405)b 1190(837.5–1380)a 1310(1135–1470)a <0.0001
FEV1 PD predicted (%) 69(60.5–81.5)c 40(32.75–50)a 59(51.5–69.5)b <0.0001
Reversibility (%) 6(0.5–10.5)a 6.5(1–11.25)a 8(2–13.5)a >0.05
FVC (mL) 3200(2625–3780)c 2427.5(1705–2767.5)a 2140(1820–2390)b <0.0001
FVC predicted (%) 86(74–99.5)c 65(55.75–74.25)a 77(68.5–85.5)b <0.0001
FVC post (mL) 3320(2805–3870)c 2385(1797.5–2900)a 2130(1870–2445)b <0.0001
FVC post (%) 90(79.5–101)c 68(56.75–76.5)a 80(71.5–91.5)b <0.0001
FEV1/ FVC pre (%) 63.1(56.45–66.65)b 47(40.37–50.42)a 57.1(53.15–64.5)b <0.0001
FEV1/ FVC post (%) 63.9(58.3–68.55)b 47.5(42.8–53.2)a 59.9(54.5–67.05)b <0.0001
TLC (mL) 6710(5725–7385)a 6945(5832.5–8107.5)a 5430(4890–6005)b <0.0001
TLC predicted (%) 103(93–112.5)b 112.5(100–125.25)a 117(102–127)a <0.001
RV (mL) 3450(2990–3820)b 4640(3687.5–5277.5)a 3250(2845–3690)b <0.0001
RV predicted (%) 141(128–173)c 182.5(162.5–228.5)a 168(145.5–189.5)b <0.0001
RV/TLC (%) 53.18(47.13–56.82)c 66.23(61.34–69.03)a 60.95(56.93–64.04)b <0.0001
DLCO (mmol/kPa.min) 5.13(3.80–5.87)b 3.55(2.69–4.45)a 3.27(2.67–4)a <0.0001
DLCO predicted (%) 56(43–67)b 42.5(30.75–57.25)a 45(38–55)a <0.0001
DLCO/AV 1(0.79–1.28)b 0.83(0.63–1.02)a 0.93(0.69–1.13)a <0.0001
DLCO/AV predicted (%) 70(56.5–88)b 66(45.75–79)a 62(50–75)a <0.001
sGaw (1/kPasec) 0.68(0.47–0.93)c 0.36(0.24–0.47)a 0.47(0.35–0.76)b <0.0001
FRC (L) 4.88(4.09–5.44)c 5.86(4.88–6.49)a 4.24(3.77–5.05)b <0.0001
FRC predicted (%) 143(122–162)c 171(154–195.75)a 161(141.5–183.5)b <0.0001
Treatment Treatment (Yes) 43.75%(28[64])a 78.84%(41[52])b 66.67%(36[54])b <0.0001
ICS (Yes) 30.30%(20[66])a 70.91%(39[55])b 69.09%(38[55])b <0.0001
OCS (Yes) 1.51%(1[66])a 14.54%(8[55])b 0%(0[55])a <0.0001
LAMA (Yes) 34.85%(23[66])a 72.73%(40[55])b 49.09%(27[55])a <0.0001
LABA (Yes) 45.45%(30[66])a 83.64%(46[55])b 76.36%(42[55])a <0.0001
SABA (Yes) 25.76%(17[66])a 50.91%(28[55])b 49.09%(27[55])b <0.001
LTRA (Yes) 3.03%(2[66])a 0%(0[55])a 7.27%(4[55])a >0.05
Theophylline (Yes) 1.51%(1[66])a 5.45%(3[55])a 1.82%(1[55])a >0.05
CAT score 22(15–31)a 26(19–30)a 24(17–30)a >0.05
Blood Leucocytes (mL) 7.44(6.44–9.43)a 8.58(7.02–10.75)a 7.77(6.64–9.2)a >0.05
Neutrophils (%) 58.9(52.75–63.75)b 68.6(61.27–73.22)a 57.7(53.25–64.55)b <0.0001
Lymphocytes (%) 30.1(25.65–35)b 20.7(15.7–26.85)a 29(23.85–35.15)b <0.0001
Monocytes (%) 8.7(7–9.8)b 7.8(6.37–9.82)a 7.1(6.4–8.75)a <0.05
Eosinophils (%) 2.1(1.1–3.25)a 1.8(0.85–3.12)a 2.1(0.95–3.35)a >0.05
Basophils (%) 0.4(0.3–0.6)a 0.3(0.2–0.52)a 0.4(0.3–0.7)a >0.05
Neutrophils (mL) 4503.6(3554.3–5501.7)b 5574.9(4116.2–7842.7)a 4840.71(3393.7–5743.1)b <0.05
Lymphocytes (mL) 2346.79(1853.9–3019.6)b 1885.8(1294.4–2424.2)a 2267.98(1846.6–2710.8)b <0.0001
Monocytes (mL) 668.82(494.15–857.91)a 707.29(534.38–864.82)a 605.82(457.16–761.76)a >0.05
Eosinophils (mL) 150.72(84.57–240.24)a 169.57(75.89–275.16)a 147.63(85.47–248.25)a >0.05
Basophils (mL) 30.84(21.37–42.16)a 27.63(18.64–47.66)a 32.04(23.95–49.36)a >0.05
Fibrinogen (g/l) 3.42(2.87–3.86)b 3.71(3.08–4.58)a 3.54(2.91–3.80)a <0.05
CRP (mg/l) 2.3(1.25–5.6)a 2.9(0.9–7.7)a 2.1(1–5.15)a >0.05
Alpha 1 antitrypsin (g/l) 1.49(1.35–1.57)b 1.63(1.39–1.76)a 1.45(1.35–1.65)b <0.05
Calcium (mmol/L) 2.42(2.37–2.47)a 2.41(2.35–2.48)a 2.44(2.38–2.48)a >0.05
25(OH) Vitamine D (ng/ml) 19(12–32)a 16.5(10–24.25)a 24(13–32.5)a >0.05
Phosphate (mmol/L) 0.89(0.79–0.95)a 0.87(0.71–1.03)a 1.01(0.93–1.12)b <0.0001
Atopy IgE (KU/L) 52(23–233.5)a 91.5(25–300.25)a 73(19–170)a >0.05
RAST DPT (d1) %>0.35 (KU/L) 13.33%(8)a 14.28%(7)a 6.12%(3)a >0.05
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measured at higher level than those usually found in a gen-
eral population of this age, maybe pointing to a role of IgE
mediated processes in the pathophysiology of the disease. It
has also been suggested that smoking may stimulate IgE
production [29]. However, it is a production clearly directed
toward something different from the classical aeroallergens
encountered in asthma. The reason why atopic status is so
low in COPD, clearly lower than in a general population, is
likely to be related to the age of the COPD patients. Indeed,
it was demonstrated in population studies that specific IgE
levels decreased with age [30] and we have shown in a large
asthmatic population that the rate of sensitization to aeroal-
lergens was sharply declining with age after 60 years [31].
Of interest, and also perhaps surprising, is the fact the
CAT score does not differ between the groups despite clear
differences in lung function impairment and extent in air-
way inflammation. This shows that CAT score cannot cap-
ture the airflow limitation nor airway inflammation,
indicating that symptoms, lung function and airway inflam-
mation are different domains accounting for the disease
variability [32].
Our study has obviously limitations as we have not taken
into account comorbidities, exercise capacity and lung imag-
ing in our parameters, which are key variables in phenotyp-
ing the COPD patients in clinical practice. Our purpose
here was rather to explore variables traditionally linked to
asthma such FeNO, IgE and eosinophilic inflammation and
to see whether they can play a significant contribution in
defining the variability of the disease in patients > 40 years
with smoking history and persistent airway obstruction. Our
data indicate that FeNO, blood eosinophils and serum IgE,
though being significantly different from what is found in a
healthy population for total serum IgE, are not able to single
out a particular cluster. Therefore, most of the T2 bio-
markers had not enough variability among the patients to
shape a cluster. However, eosinophilic (together with neu-
trophilic) airway inflammation is raised in the cluster that
shows the most severe lung function impairment. These
data may have importance as it has been shown by retro-
spective post hoc analysis that ICS treatment in eosinophilic
COPD might actually slow down the lung function decline
[33]. The impact of targeting eosinophilic inflammation in
COPD should be given careful consideration in long term
clinical trials using not only ICS but also anti-interleukine-5.
Another important limitation of our study is the lack of a
validation cohort whereas Castaldi et al have shown that
reproducibility of COPD clustering across studies was rather
modest. The size of our cohort was however too small to
split our population and perform meaningful clustering with
our extensive set of variables. However, we presented valid-
ation with two statistical indices.
In conclusion, in a cohort of COPD we found 3 clusters
of patients with similar age and smoking history but very
different sex distributions and lung function and inflamma-
tory parameter. In particular, we identified a cluster of male
patients with intense granulocytic airway inflammation com-
bined with severe airway flow limitation and lung hyperdis-
tention, who are prone to exacerbate and undergo recurrent
hospitalizations. These clusters need to be confirmed in a
new cohort of patients, ideally from other centers.
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Result for clustering on raw dataset
P-valueCluster 1 Cluster 2 Cluster 3
RAST Cat (e1), %>0.35 (KU/L) 1.64%(1)a 8.16%(4)a 2%(1)a >0.05
RAST Dog (e5), %>0.35 (KU/L) 3.28%(2)a 6.12%(3)a 0%(0)a >0.05
RAST Grass (GX3), %>0.35 (KU/L) 6.67%(4)a 12.24%(6)a 2.04%(1)a >0.05
RAST microog (MIX1), %>0.35 (KU/L) 6.56%(4)a 12.24%(6)a 10%(5)a >0.05
RAST Birch (t3), %>0.35 (KU/L) 0%(0)a 4.08%(2)a 0%(0)a >0.05
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COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 11
2. Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbid-
ities of COPD. Eur Respir J. 2008;31(1):204–212. DOI:10.1183/
09031936.00114307
3. Deliu M, Sperrin M, Belgrave D, et al. Identification of asthma
subtypes using clustering methodologies. Pulm Ther. 2016;2:
19–41. DOI:10.1007/s41030-016-0017-z
4. Johnson RA, Wichern DW. Applied multivariate statistical ana-
lysis: international edition. 6th ed. Pearson; ISBN-13 : 978-
0135143506 Publisher: Pearson (4 May 2007)
5. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clin-
ical asthma phenotypes. Am J Respir Crit Care Med. 2008;
178(3):218–224. DOI:10.1164/rccm.200711-1754OC
6. Moore WC, Meyers DA, Wenzel SE, National Heart, Lung, and
Blood Institute’s Severe Asthma Research Program, et al.
Identification of asthma phenotypes using cluster analysis in the
severe asthma research program. Am J Respir Crit Care Med.
2010;181(4):315–323. DOI:10.1164/rccm.200906-0896OC
7. Castaldi PJ, Benet M, Petersen H, et al. Do COPD subtypes
really exist? COPD heterogeneity and clustering in 10 independ-
ent cohorts. Thorax. 2017;72(11):998–1006. DOI:10.1136/thor-
axjnl-2016-209846
8. Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of
comorbidities based on validated objective measurements and
systemic inflammation in patients with chronic obstructive pul-
monary disease. Am J Respir Crit Care Med. 2013;187(7):
728–735. DOI:10.1164/rccm.201209-1665OC
9. Burgel P-R, Roche N, Paillasseur J-L, INITIATIVES BPCO
Scientific Committee, et al. Clinical COPD phenotypes identified
by cluster analysis: validation with mortality. Eur Respir J. 2012;
40(2):495–496. DOI:10.1183/09031936.00228511
10. Burgel P-R, Paillasseur J-L, Caillaud D, Initiatives BPCO
Scientific Committee, et al. Clinical COPD phenotypes: a novel
approach using principal component and cluster analyses. Eur
Respir J. 2010;36(3):531–539. DOI:10.1183/09031936.00175109
11. Garcia-Aymerich J, Gomez FP, Benet M, on behalf of the PAC-
COPD Study Group, et al. Identification and prospective valid-
ation of clinically relevant chronic obstructive pulmonary disease
(COPD) subtypes. Thorax. 2011;66(5):430–437. DOI:10.1136/thx.
2010.154484
12. Fens N, van Rossum AGJ, Zanen P, et al. Subphenotypes of
mild-to-moderate COPD by factor and cluster analysis of pul-
monary function, CT imaging and breathomics in a population-
based survey. COPD J Chronic Obstr Pulm Dis. 2013;10(3):
277–285. DOI:10.3109/15412555.2012.744388
13. Basaga~na X, Barrera-Gomez J, Benet M, et al. A framework for
multiple imputation in cluster analysis. Am J Epidemiol. 2013;
177(7):718–725. DOI:10.1093/aje/kws289
14. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a
predominant COPD phenotype in clinical practice. Respir Med.
2008;102(3):367–376. DOI:10.1016/j.rmed.2007.10.019
15. Paoletti M, Camiciottoli G, Meoni E, et al. Explorative data ana-
lysis techniques and unsupervised clustering methods to support
clinical assessment of Chronic Obstructive Pulmonary Disease
(COPD) phenotypes. J Biomed Inform. 2009;42(6):1013–1021.
DOI:10.1016/j.jbi.2009.05.008
16. Burgel P-R, Nesme-Meyer P, Chanez P, et al. Cough and sputum
production are associated with frequent exacerbations and hospi-
talizations in COPD subjects. Chest. 2009;135(4):975–982. DOI:
10.1378/chest.08-2062
17. Burgel P-R, Paillasseur J-L, Peene B, et al. Two distinct chronic
obstructive pulmonary disease (COPD) phenotypes are
associated with high risk of mortality. Sethi. S, ed. PLoS ONE.
2012;7(12):e51048. DOI:10.1371/journal.pone.0051048
18. Burgel P-R, Paillasseur J-L, Janssens W, et al. A simple algorithm
for the identification of clinical COPD phenotypes. Eur Respir J.
2017;50(5):1701034. DOI:10.1183/13993003.01034-2017
19. Burgel P-R, Paillasseur J-L, Roche N. Identification of clinical
phenotypes using cluster analyses in COPD patients with mul-
tiple comorbidities. BioMed Res Int. 2014;2014:420134–420139.
DOI:10.1155/2014/420134
20. Cataldo D, Corhay J-L, Derom E, et al. A Belgian survey on the
diagnosis of asthma-COPD overlap syndrome. COPD. 2017;
Volume 12:601–613. DOI:10.2147/COPD.S124459
21. Molenberghs G, Kenward M. Missing data in clinical studies.
John Wiley & Sons; ISBN:9780470849811 Publisher is: John
Wiley & Sons: Chichester, 2007.
22. Buuren S. v. Flexible imputation of missing data. CRC Press;
ISBN-13: 978-1439868249 Publisher: Chapman and Hall/CRC;
1st Edition (March 29, 2012).
23. Rubin DB. Multiple imputation for nonresponse in surveys. John
Wiley & Sons; ISBN:0470317361, 9780470317365 Publisher: John
Wiley & Sons, Inc. 2009.
24. Agusti A, Pavord ID. Do we really need a new classification of
airway diseases? Lancet Respir Med. 2018;6(12):891–893. DOI:10.
1016/S2213-2600(18)30386-2
25. Moermans C, Heinen V, Nguyen M, et al. Local and systemic
cellular inflammation and cytokine release in chronic obstructive
pulmonary disease. Cytokine. 2011;56(2):298–304. DOI:10.1016/j.
cyto.2011.07.010
26. Celli BR, Locantore N, Yates J, for the ECLIPSE Investigators,
et al. Inflammatory biomarkers improve clinical prediction of
mortality in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med. 2012;185(10):1065–1072. DOI:10.1164/rccm.
201110-1792OC
27. Demarche S, Schleich F, Henket M, et al. Detailed analysis of
sputum and systemic inflammation in asthma phenotypes: are
paucigranulocytic asthmatics really non-inflammatory? BMC
Pulm Med. 2016;16(1):46. DOI:10.1186/s12890-016-0208-2
28. Schleich FN, Chevremont A, Paulus V, et al. Importance of con-
comitant local and systemic eosinophilia in uncontrolled asthma.
Eur Respir J. 2014;44(1):97–108. DOI:10.1183/09031936.
00201813
29. O’Connor GT, Sparrow D, Weiss ST. The role of allergy and
nonspecific airway hyperresponsiveness in the pathogenesis of
chronic obstructive pulmonary disease. Am Rev Respir Dis.
1989;140(1):225–252. DOI:10.1164/ajrccm/140.1.225
30. Amaral AFS, Newson RB, Abramson MJ, et al. Changes in IgE
sensitization and total IgE levels over 20 years of follow-up. J
Allergy Clin Immunol. 2016;137(6):1788–1795.e9. DOI:10.1016/j.
jaci.2015.09.037
31. Manise M, Bakayoko B, Schleich F, et al. IgE mediated sensitisa-
tion to aeroallergens in an asthmatic cohort: relationship with
inflammatory phenotypes and disease severity. Int J Clin Pract.
2016;70(7):596–605. DOI:10.1111/ijcp.12837
32. Lapperre TS, Snoeck-Stroband JB, Gosman MME, Groningen
and Leiden Universities Corticosteroids in Obstructive Lung
Disease Study Group, et al. Dissociation of lung function and
airway inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2004;170(5):499–504. DOI:10.1164/
rccm.200401-112OC
33. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and
inhaled corticosteroid/long-acting b-2 agonist efficacy in COPD.
Thorax. 2016;71(2):118–125. DOI:10.1136/thoraxjnl-2015-207021
12 H. N. ZAHRAEI ET AL.
